GlassScriptPhysician profile
Kerry M Shafran
NPI 1740394543
$3,223.01
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $424 · 2021: $400 · 2022: $737 · 2023: $407 · 2024: $20.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $603.16 | 2019 | |
| Janssen Biotech, INC. | $583.57 | 2019-2022 | |
| Abbvie INC. | $462.06 | 2019-2023 | Skyrizi, Rinvoq |
| Allergan, INC. | $387.93 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $236.66 | 2019-2023 | |
| Medimetriks Pharmaceuticals, INC. | $192.43 | 2019-2023 | Neo-Synalar |
| Genzyme Corporation | $152.27 | 2020-2023 | |
| Galderma Laboratories, L.P. | $135.95 | 2019-2024 | Aklief, Oracea, Twyneo |
| Regeneron Healthcare Solutions, INC. | $98.68 | 2019-2023 | Dupixent |
| Sun Pharmaceutical Industries INC. | $76.20 | 2019-2023 | Winlevi |
| Vyne Pharmaceuticals INC. | $53.22 | 2021 | |
| Leo Pharma INC. | $37.96 | 2021-2022 | |
| Amgen INC. | $34.55 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.94 | 2022 | |
| Biofrontera INC. | $31.13 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.75 | 2020 | |
| Incyte Corporation | $19.74 | 2021 | |
| Mayne Pharma Commercial LLC | $18.48 | 2020 | |
| Sebela Pharmaceuticals INC. | $16.52 | 2019 | |
| Almirall LLC | $14.76 | 2020 | |
| Dusa Pharmaceuticals, INC. | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Shafran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.